Palo Alto/Princeton/Lucerne, February 15, 2018. In addition to celebrating its 26th company anniversary this year, INOVIS further enhances its well-regarded strategic consulting services by appointing a highly driven, experienced and respected pharma industry expert to run the firm's rapidly growing division.
INOVIS is proud to announce today that it has appointed Dr. Harshal Kubavat as its Head of Strategic Consulting Services. Harshal brings the benefit of having both client and agency experience and hence offering a high degree of understanding of brand and competitor strategies, empathy for clients' needs and pain points, but equally importantly, new innovative and pioneering ideas to enable and optimize brand and competitor strategies. Overall, Harshal's extensive experience with the pharma industry through academic, patient-facing and commercial activities over the past ten years provide a tremendous value to brand and competitor strategy optimization, workshops, scenario planning and development of strategic frameworks.
He joins us from Roche Pharmaceuticals where he spent four years: the first two as Global International CI Manager, working for Roche's Global Product Strategy team covering pipeline and on-market assets; he most recently was a brand manager at Roche Products Ltd in the UK, where he was responsible for marketing activities for multiple brands, leveraging his extensive experience to drive and shape a number of market facing and internal activities, including marketing materials, tender strategies, and managing the impact of generic competition. Prior, he worked for a CI consulting agency, running projects for a wide range of pharma clients in different therapeutic areas to help guide client strategy. Harshal holds a PhD in Pharmaceutical Drug Delivery from Bath University (UK) and is a UK-registered pharmacist, gaining his Master of Pharmacy at the School of Pharmacy, University of London.
In his new role at INOVIS, Harshal is responsible for managing the firm's Strategic Consulting Services unit, which consists mainly of brand strategy optimization, workshops, scenario planning, LCM, competitor simulations ('war gaming') as well as competitive strategy training sessions to pharma, biotech, medical devices & digital medicine clients. He reports to Dr. Baljit Singh, Managing Director and Partner in INOVIS' Global Pharmaceuticals and Life Sciences Division.
This appointment attests to INOVIS' growth strategy aimed at improving competitive strategies for our clients through experienced senior industry talent who can enable further strategic thinking with impact on company and brand strategies. Furthermore, INOVIS' unique Client Strategy and Experience Optimization (CSEO) process is aimed at maximizing each client's collaboration and partnership experience with INOVIS - including strategic consulting - to achieve the highest possible ROI, which in turns fosters long-term, decade-long client partnerships. This latest senior team expansion exemplifies Limacher's and Singh's commitment to continue to be at the forefront of the CI and strategic consulting industry. 'Harshal's tested and proven track record and experience in running strategy workshops in Big Pharma environments bring implications analysis and scenarios 'alive' by entertaining, engaging and ultimately actionable client team interactions and outcomes, leading to tangible bottom line results and ROI for our loyal clientele,' says Marc Limacher, INOVIS' Founder & CEO. 'We are extremely excited to have Dr Harshal Kubavat lead our strategic consulting business. He is a proven high performer and exceptionally talented. His significant scientific and commercial background, combined with his positive to-do attitude makes him a perfect fit to help drive and enable company and brand strategies' says Baljit Singh, INOVIS' Managing Director & Partner.